348-66-3

Basic information

• Product Name: D-ornithine
• Synonyms: (2R)-2,5-diaminopentanoic acid;CPD-217
• CAS NO: 348-66-3
• Molecular Formula: C₅H₁₂N₂O₂
• Molecular Weight: 133.17042
• EINECS: 206-482-0
• Mol File: 348-66-3.mol

Chemical Properties

• Melting Point: 140 °C
• Boiling Point: 308.7±32.0 °C(Predicted)
• Appearance: /
• Density: 1.165±0.06 g/cm3(Predicted)
• PKA: 2.45±0.24(Predicted)
• CAS DataBase Reference: D-ornithine(CAS DataBase Reference)
• NIST Chemistry Reference: D-ornithine(348-66-3)
• EPA Substance Registry System: D-ornithine(348-66-3)

Safety Data

• Hazardous Substances Data: 348-66-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
D-ornithine is used as a therapeutic agent for promoting wound healing and enhancing immune function. It is particularly effective in treating conditions such as burns, trauma, and sepsis, where rapid tissue repair and immune support are critical.
Used in Sports Nutrition:
In the sports nutrition industry, D-ornithine is used as a supplement to improve athletic performance and support muscle growth. It is believed to enhance the production of growth hormone and insulin-like growth factor-1 (IGF-1), which are essential for muscle development and recovery.
Used in Cosmetics:
D-ornithine is also used in the cosmetics industry for its potential anti-aging and skin-protective properties. It may help improve skin elasticity and reduce the appearance of fine lines and wrinkles, making it a valuable ingredient in anti-aging skincare products.
Used in Research:
In the field of scientific research, D-ornithine serves as an important compound for studying the urea cycle and related metabolic pathways. It is used as a research tool to better understand the role of ornithine in various biological processes and to develop new therapeutic strategies for various diseases.

Upstream product

• 1892-22-4 3-aminopiperidin-2-one 
• 70-26-8 D-ornithine 
• 542-32-5 (R,S)-2-aminoadipic acid 
• 157-06-2 D-arginine 
• 74-79-3 L-arginine 
• 627-77-0 citrulline 
• 15920-89-5 N^α-carbamoyl-L-arginine 
• 4435-48-7 butane-1,1,4-tricarboxylic acid 
• 5440-42-6 ethyl 2-acetamido-4-cyano-2-ethoxycarbonylbutanoate 
• 7438-77-9 Orn-δ-NOH 
• 3928-25-4 N,N'-bis-(pyridine-2-carbonyl)-ornithine 
• 26464-30-2 2-chloro-5-phthalimido-pentanoic acid 
• 7664-41-7 ammonia 
• 7732-18-5 water 

Downstream Products

• 5058-01-5 3-hydroxytetrahydro-2H-pyran-2-one 
• 2000-59-1 5-amino-2-oxo-valeric acid 
• 110-60-1 1,4-diaminobutane 
• 5724-81-2 1-pyrroline 
• 105909-34-0 α-keto-δ-aminovaleric acid 2,4-dinitrophenylhydrazone 
• 70671-51-1 N⁵-benzyloxycarbonyl-DL-ornithine 
• 99780-98-0 (+/-)-3-<(tert-butoxycarbonyl)amino>-2-piperidone 
• 74-79-3 L-arginine 
• 70-26-8 2,5-diaminopentanoic acid 
• 13594-51-9 D-citrulline 
• 97974-52-2 (2S,5S,12R)-12-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-2-isobutyl-3,7,13-trioxo-1,4,8-triaza-cyclotridecane-5-carboxylic acid amide 
• 96382-72-8 H-Tyr-D-Orn[*]-Phe-Asp[*]-NH2 
• 106732-42-7 (2S,5S,12R,15S,18S,25R)-12,25-Bis-[(S)-2-amino-3-(4-hydroxy-phenyl)-propionylamino]-2,15-dibenzyl-3,7,13,16,20,26-hexaoxo-1,4,8,14,17,21-hexaaza-cyclohexacosane-5,18-dicarboxylic acid diamide 
• 2274-58-0 N,N'-di(benzyloxycarbonyl)-D-ornithine 

Relevant articles and documents

Catenulobactins A and B, Heterocyclic Peptides from Culturing Catenuloplanes sp. with a Mycolic Acid-Containing Bacterium

The production of two new heterocyclic peptide isomers, catenulobactins A (1) and B (2), in cultures of Catenuloplanes sp. RD067331 was significantly increased when it was cocultured with a mycolic acid-containing bacterium. The planar structures and absolute configurations of the catenulobactins were determined based on NMR/MS and chiral-phase GC-MS analyses. Catenulobactin B (2) displayed Fe(III)-chelating activity and moderate cytotoxicity against P388 murine leukemia cells.

A new ureido-substituted amino acid from the tubers of Gymnadenia conopsea

A new ureido-substituted amino acid, conopsamide A (1), has been isolated from an ethanolic extract of the tubers of Gymnadenia conopsea. Its structure was elucidated by extensive spectroscopic analysis, and the absolute configuration was assigned by Marfey's method. The new compound was evaluated for in vitro assay for HDAC1 (Histone Deacetylase 1) inhibitory activity.

FUNCTIONALIZED FLUORINE CONTAINING PHTHALOCYANINE MOLECULES

Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.

Immunomodulatory peptides

The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.

GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

Lysine racemase from a lactic acid bacterium, Oenococcus oeni: Structural basis of substrate specificity

Oenococcus oeni, a lactic acid bacterium, possesses a lysine racemase, which has a specific activity towards basic amino acids. A comparison of amino acid residues around the active site suggested that Ile222 and Tyr354 of the Geobacillus stearothermophilus alanine racemase, which shares 60% sequence similarity with lysine racemase, were replaced by Thr224 and Trp355 in the O. oeni lysine racemase. T224I/W355Y double mutations significantly decreased the activity of lysine racemase, whereas I222T/Y354W double mutations endowed alanine racemase with lysine racemization activity. These results suggest that the two residues play an important role in lysine racemization.

NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS

The invention relates to a compound of the formula (I): in which k and j are independently 0 or 1, Y is a macrocycle in which the cycle includes 9 to 36 carbon atoms and is functionalised by three amino functions and by a chain for attaching the spacer arm Z via an X bond, Rc is a binding pattern with a receptor of the TNF superfamily, X is a chemical function for binding the Y group to the space arm, and Z is a bi-, tri- or tetra-functional spacer arm.

NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS

The invention concerns a compound of formula (I), wherein Y represents a macrocycle whereof the cycle comprises 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rc represents a group of formula H—Xa—Xb—Xc—Xd—Xe—(Xf)i—, wherein i represents 0 or 1, Xn is in particular selected among lysine, arginine, ornithine residues, Xb is in particular selected among glycine, asparagine, L-proline or D-proline residues, Xc et Xd are in particular selected among tyrosine, phenylalanine or 3-nitrotyrosine residues, Xe et Xf are in particular selected among the following amino acid residues: NH2—(CH2)n—COOH, n ranging from 1 to 10 or NH2—(CH2—CH2—O)m—CH2CH2COOH, m ranging from 3 to 6, provided that one at least of the amino acid residues Xa, Xb, Xc and Xd is different from the corresponding amino acid in the sequence of the natural CD40 143Lys-Gly-Tyr-Tyr146 fragment

Cyclic dipeptide of D-ornithine obtained from the dobsonfly, Protohermes grandis thunberg

A new compound was isolated from the water-soluble fraction of a methyl alcohol extract obtained from the larva of the dobsonfly (Protohermes grandis Thunberg). The novel compound had a 12-membered ring and was confirmed to be a cyclic dipeptide of D-orni

Process for producing alpha 2,3/ alpha 2,8-sialyltransferase and sialic acid-containing complex sugar

The present invention can provide a process for producing a protein having α2,3/α2,8-sialyltransferase activity using a transformant comprising a DNA encoding a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a sialic acid-containing complex carbohydrate using a transformant capable of producing a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism.